Anagestone
Clinical data
Other namesAnapregnone; 3-Deketo-6α-methyl-17α-hydroxyprogesterone; 6α-Methyl-17α-hydroxypregn-4-en-20-one
Identifiers
  • 1-[(6S,8R,9S,10R,13S,14S,17R)-17-Hydroxy-6,10,13-trimethyl-1,2,3,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H34O2
Molar mass330.512 g·mol−1
3D model (JSmol)
  • CC1CC2C(CCC3(C2CCC3(C(=O)C)O)C)C4(C1=CCCC4)C
  • InChI=1S/C22H34O2/c1-14-13-16-18(20(3)10-6-5-7-17(14)20)8-11-21(4)19(16)9-12-22(21,24)15(2)23/h7,14,16,18-19,24H,5-6,8-13H2,1-4H3/t14-,16+,18-,19-,20-,21-,22-/m0/s1
  • Key:GAIHSQSRHYQICG-DACBVQKSSA-N

Anagestone (INNTooltip International Nonproprietary Name), also known as 3-deketo-6α-methyl-17α-hydroxyprogesterone or as 6α-methyl-17α-hydroxypregn-4-en-20-one, is a progestin which was never marketed.[1]

An acylated derivative, anagestone acetate, was formerly used clinically as a pharmaceutical drug.[1]

While anagestone is sometimes used as a synonym for anagestone acetate, it usually refers to anagestone acetate, not anagestone.

References

  1. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 85–. ISBN 978-1-4757-2085-3.



Categories